Eikon Therapeutics’ lead drug candidate is designed to activate toll-like receptors 7 and 8, sparking an immune response that fights cancer. Beyond this TLR7/8 agonist, the biotech is also developing PARP inhibitors that could have advantages over cancer drugs currently available from this class.
The post Eikon Raises $350M for Cancer Drug Pipeline Led by Melanoma Med in Pivotal Testing appeared first on MedCity News.
